<code id='5AA373B2F4'></code><style id='5AA373B2F4'></style>
    • <acronym id='5AA373B2F4'></acronym>
      <center id='5AA373B2F4'><center id='5AA373B2F4'><tfoot id='5AA373B2F4'></tfoot></center><abbr id='5AA373B2F4'><dir id='5AA373B2F4'><tfoot id='5AA373B2F4'></tfoot><noframes id='5AA373B2F4'>

    • <optgroup id='5AA373B2F4'><strike id='5AA373B2F4'><sup id='5AA373B2F4'></sup></strike><code id='5AA373B2F4'></code></optgroup>
        1. <b id='5AA373B2F4'><label id='5AA373B2F4'><select id='5AA373B2F4'><dt id='5AA373B2F4'><span id='5AA373B2F4'></span></dt></select></label></b><u id='5AA373B2F4'></u>
          <i id='5AA373B2F4'><strike id='5AA373B2F4'><tt id='5AA373B2F4'><pre id='5AA373B2F4'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:comprehensive    Page View:441
          Boston Scientific headquarters -- Health coverage from STAT
          Boston Scientific is growing its urology portfolio with the Axonics acquisition. Steven Senne/AP

          Boston Scientific said it will buy Axonics, a device company treating urinary and bowel disorders, on Monday. The deal is worth $3.7 billion.

          It’s the first billion-dollar medical device deal of 2024 — a rare occurrence in 2023, which saw just a handful of medtech acquisitions reaching the billion threshold. Boston Scientific said it expects to close the deal in the first half of this year. Axonics’ stock increased by 20% in light of the news; Boston Scientific’s dropped slightly.

          advertisement

          Boston Scientific has acquired companies across all medtech sectors in the past year. The device maker bought Apollo Endosurgery, a company selling surgical tools to combat obesity, for $615 million in 2023. In September of 2023, Boston Scientific bought pain relief company Relievant for $850 million.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Novavax promises a turnaround & Lilly roils the obesity market
          Novavax promises a turnaround & Lilly roils the obesity market

          SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

          read more
          Pumping milk in bathrooms at health conferences is common
          Pumping milk in bathrooms at health conferences is common

          AdobeEventhoughErinBoothwasnotthrilledabouthavingtotraveltoPhiladelphiaforaconferenceatsixweekspostp

          read more
          Supreme Court strikes down use of affirmative action
          Supreme Court strikes down use of affirmative action

          ActivistsdemonstratedastheSupremeCourtheardoralargumentsonapairofaffirmativeactioncasesinOctober2022

          read more

          Readout Newsletter: Parkinson's study, Gilead, CG Oncology

          AdobeWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsletterinyo